Atrial Flutter (AFL)
Details
Atrial flutter is one of the most common atrial tachyarrhythmias, typically arising from a macro-reentrant circuit in the right atrium dependent on the cavo-tricuspid isthmus (CTI). It is closely associated with atrial fibrillation, sharing similar risk factors, and the majority of AFL patients eventually develop AF.
Key Facts
- Incidence: 88 per 100 000 person-years overall; rises to 317 per 100 000 person-years in people >50 years (sources/AF-ESC-2024, rating: very high)
- More than 50% of all patients with AFL will develop AF during follow-up (sources/AF-ESC-2024)
- Thromboembolic risk is elevated in AFL; observational data show similar or slightly lower stroke risk vs. AF, possibly due to confounders (comorbidity, anticoagulation patterns) (sources/AF-ESC-2024)
- OAC recommended in AFL patients at elevated thromboembolic risk (CHA2DS2-VA), analogous to AF management (Class I/B) (sources/AF-ESC-2024)
- Rate control can be difficult in AFL; rhythm control with CTI ablation is often first-line (sources/AF-ESC-2024)
- CTI ablation is superior to antiarrhythmic drugs for typical AFL (small RCTs); bidirectional block in the CTI is the procedural endpoint (sources/AF-ESC-2024)
- AFL recurrence is uncommon after confirmed bidirectional CTI block; however, 50–70% of patients develop AF during long-term follow-up after AFL ablation (sources/AF-ESC-2024)
- Long-term dynamic reassessment (AF-CARE approach) is essential for all AFL patients given the high rate of subsequent AF development (sources/AF-ESC-2024)
- Management of comorbidities and risk factors in AFL mirrors the approach for AF (sources/AF-ESC-2024)
AHA 2023 Anticoagulation Recommendations for AFL
- OAC recommended per same risk profile as AF (Class I/B-NR) (sources/AF-AHA-2023, rating: very high)
- OAC continued ≥4 weeks after cardioversion or ablation (Class I/C-LD) (sources/AF-AHA-2023)
- Patients with prior AF before CTI ablation: ongoing OAC as for AF (Class I/A) (sources/AF-AHA-2023)
- Patients without prior AF after successful CTI ablation at high stroke risk: close AF monitoring recommended (Class I/B-NR); if at high risk for AF development (LA enlargement, inducible AF, COPD, HF), long-term OAC may be reasonable (Class IIb/B-NR) (sources/AF-AHA-2023)
- AF incidence after CTI ablation: 16–82% in long-term follow-up; in one series, 82% developed AF over 39 months follow-up (sources/AF-AHA-2023)
- Stroke rate in AFL patients without anticoagulation: 4.1% vs. 1.2% in matched controls (sources/AF-AHA-2023)
- AFL is 2.5× more common in men; higher incidence in HF and COPD (sources/AF-AHA-2023)
Contradictions / Open Questions
- Some studies suggest lower stroke risk in AFL vs. AF; others show similar risk — the true thromboembolic risk differential remains uncertain, likely influenced by the frequent co-occurrence of both arrhythmias (sources/AF-ESC-2024, sources/AF-AHA-2023)
Connections
- Related to entities/Atrial-Fibrillation
- Related to concepts/AF-CARE
- Related to concepts/CHA2DS2-VA